

## Glenmark to market Fluticasone DPI in Germany

10 September 2018 | News

**This approval affirms Glenmark's capabilities in the complex inhaled respiratory products segment**



Glenmark Pharmaceuticals Ltd., a research-led global integrated pharmaceutical company announced that its subsidiary Glenmark Arzneimittel GmbH has secured marketing authorization in Germany for Fluticasone/Salmeterol Dry Powder Inhaler (DPI), a generic version of GlaxoSmithKline's Seretide® Accuhaler®.

Fluticasone/Salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark will sell the product in Germany under the name 'SALFLUTIN'.

Glenmark had entered into a strategic development and licensing agreement with Celon Pharma S.A. (Celon) in 2015 to develop and market generic Fluticasone/Salmeterol DPI in 15 European countries.

The company has already launched this product in Denmark, Sweden and Norway.

According to IQVIA data, Fluticasone/Salmeterol Dry Powder Inhaler (DPI) had sales of USD 844 million in Europe in the 12 month period ended March 2018.